Please try another search
For the nine months ended 30 September 2018, Akers Biosciences Inc revenues decreased 43% to $1.4M. Net loss increased from $3.3M to $7M. Revenues reflect License & Service Revenue decrease from $38K to $0K. Higher net loss reflects Administrative Expenses increase of 69% to $4.1M (expense), Sales and Marketing Expenses increase of 3% to $1.3M (expense), Research and Development Expenses - Rela increase from $23K to $54K (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 0.56 | 0.53 | 0.3 | 0.94 |
Gross Profit | 0.08 | 0.22 | 0 | -0.59 |
Operating Income | -3.12 | -2.11 | -1.89 | -3.25 |
Net Income | -3.08 | -2.07 | -1.86 | -4.02 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 10.02 | 12.65 | 12.8 | 9.34 |
Total Liabilities | 2.3 | 1.85 | 1.38 | 1.79 |
Total Equity | 7.72 | 10.79 | 11.42 | 7.55 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -5.87 | -3.82 | -1.8 | -5.08 |
Cash From Investing Activities | 0.08 | -3 | -3.71 | -5.01 |
Cash From Financing Activities | 7.16 | 7.16 | 5.72 | 10.46 |
Net Change in Cash | 1.36 | 0.34 | 0.21 | 0.37 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review